Suppr超能文献

[室上性心律失常的药物治疗]

[Drug therapy in supraventricular arrhythmia].

作者信息

Follath F, Candinas R, Meyer B

机构信息

Departement für Innere Medizin, Universitätsspital Zürich.

出版信息

Schweiz Rundsch Med Prax. 1992 Apr 28;81(18):579-81.

PMID:1594845
Abstract

In view of their potentially dangerous proarrhythmic effects, antiarrhythmic drugs should only be prescribed for patients with poorly tolerated symptomatic supraventricular arrhythmias. The choice of a suitable preparation depends not only on the type of arrhythmia, but also on the underlying heart disease and left-ventricular function. Digoxin, verapamil, sotalol and quinidine remain first-line drugs, while in view of recent trials the type-1c antiarrhythmics (flecainide) should only be given in cases resistant to other agents. Amiodarone is also an important and efficacious "reserve" antiarrhythmic, which has to be utilized at low doses to avoid its well-known side effects.

摘要

鉴于抗心律失常药物潜在的致心律失常危险作用,仅应为症状性室上性心律失常耐受性差的患者开具此类药物。合适制剂的选择不仅取决于心律失常的类型,还取决于基础心脏病和左心室功能。地高辛、维拉帕米、索他洛尔和奎尼丁仍是一线药物,而鉴于近期试验,Ic类抗心律失常药物(氟卡尼)仅应用于对其他药物耐药的病例。胺碘酮也是一种重要且有效的“备用”抗心律失常药物,必须低剂量使用以避免其众所周知的副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验